Sponsors (4)
The bill aims to accelerate development, review, and VA-era deployment of psychedelic and other investigational therapies—potentially bringing faster treatment options for veterans and many patients—while trading off increased safety/diversion risks, privacy and legal uncertainties, and substantial administrative and cost burdens on agencies, providers, and taxpayers.
Patients with serious mental illness and substance use disorders could gain substantially faster access to new psychedelic and other investigational therapies because the bill mandates expedited rescheduling, FDA review deadlines, quota revisions, and priority-review vouchers tied to approved or breakthrough-designated products.
Veterans could see improved access and delivery of emerging therapies because the VA must designate a senior official, coordinate with HHS/FDA/DoD/DOJ, implement pilot programs, and report to Congress, which should speed navigation of regulatory pathways and program implementation in VA care.
Researchers, clinicians, and manufacturers will get clearer pathways and more evidence generation through required interagency data-sharing, federally supported state/tribal pilot programs, and provisions that prioritize clinical-trial enrollment and breakthrough-designated drugs, accelerating research and real‑world safety data collection.
Millions could face increased safety and diversion risks because the bill accelerates rescheduling, shortens FDA/DEA review timelines, expands legal access to Schedule I drugs, and allows faster quota increases—potentially outpacing safeguards and monitoring.
Participants in trials and pilot programs could face privacy and confidentiality risks because the bill mandates interagency clinical data-sharing and state/tribal reporting that may inadequately protect reidentification or sensitive health information.
Federal agencies, VA, healthcare institutions, and clinicians will incur substantial administrative and compliance burdens—staff time for expedited reviews, frequent reporting, new credentialing, registrations, security, and implementing data‑sharing agreements—diverting resources from existing priorities.
Based on analysis of 12 sections of legislative text.
Speeds DEA rescheduling for proven psychedelic therapies, defines ibogaine, creates DEA registration for clinician use, launches an FDA priority-review voucher pilot, and funds research/VA readiness and data-sharing programs.
Official title: To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.
Introduced June 30, 2026 by Morgan Luttrell · Last progress June 30, 2026
Creates several reforms to speed development, review, and clinical access to psychedelic drugs (including ibogaine) intended to treat serious mental health disorders. It directs the Attorney General to start fast-track rescheduling for Schedule I drugs that complete FDA Phase 3 trials, requires a 60-day review step specifically for ibogaine, and sets up a special DEA registration pathway so physicians can directly administer certain Schedule I investigational drugs under Right to Try. Also directs VA and HHS to establish coordination, reporting, workforce planning, and data-sharing to expand clinical trial participation and real-world evidence generation; authorizes a voucher pilot to secure FDA priority review for qualifying products; and funds state/tribal partnerships for psychedelic research through ARPA-H/NIH channels. The bill changes drug scheduling procedures, regulatory timelines, research supports, and VA program responsibilities to accelerate clinical availability of psychedelic therapies while adding controls intended to limit diversion and guide workforce readiness.